4.2 Article

Mutation spectrum in HNPCC in the Israeli population

期刊

FAMILIAL CANCER
卷 7, 期 4, 页码 309-317

出版社

SPRINGER
DOI: 10.1007/s10689-008-9191-y

关键词

Ashkenazi; Colorectal cancer; HNPCC; Israeli; Lynch; Oncogenetic; MMR; MSI

资金

  1. Israeli Cancer Association

向作者/读者索取更多资源

Hereditary non-polyposis colon cancer is caused by mutations in DNA mismatch repair genes. The mutation spectrum in the Israeli population is poorly documented except for the c.1906G > C Ashkenazi founder mutation in the hMSH2 gene. To report our experience in HNPCC screening, the mutations detected and the clinical features among a cohort of Israeli patients. Diagnostic work-up was done in a multi-step process guided by clinical and ethnic information. Tumors of suspected patients were tested for microsatellite instability and immunohistochemistry. Based on tumor analyses, we proceeded to mutation screening by DHPLC followed by sequence analysis and multiplex ligase dependent probe amplification. Ashkenazi Jews were first tested for the c.1906G > C founder mutation. Of the 240 families, 24, including Arabs and Jews from different ethnic origins, were tested positive. All tumors that lost expression of mismatch repair proteins also showed microsatellite instability. There was evidence for involvement of hMSH2 (15) hMLH1 (6) and hMSH6 (3) genes. Mutations were identified in 17/24 (71%) patients: 6 Ashkenazi families harbored the c.1906G > C mutation. Eleven other mutations (2 nonsense, 3 splice site and 6 small deletions) were detected. Three of the mutations are novel. No gross deletions or insertions were detected. This is the first report that characterizes the profile of HNPCC in a cohort of patients in Israel. Tumor testing indicated that the 3 main MMR genes are involved, and that mutation spectrum is broad.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Medicine, General & Internal

Hepatocellular carcinoma

Josep M. Llovet, Robin Kate Kelley, Augusto Villanueva, Amit G. Singal, Eli Pikarsky, Sasan Roayaie, Riccardo Lencioni, Kazuhiko Koike, Jessica Zucman-Rossi, Richard S. Finn

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge with rising incidence projected to exceed 1 million cases by 2025. Infection by hepatitis B and C viruses remains a major risk factor for HCC, while non-alcoholic steatohepatitis is emerging as a more common risk factor in Western countries. Advances in systemic therapies for HCC, including immunotherapies and targeted therapies, are expected to revolutionize the management of this disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

Article Gastroenterology & Hepatology

Senolytic elimination of Cox2-expressing senescent cells inhibits the growth of premalignant pancreatic lesions

Dror Kolodkin-Gal, Lior Roitman, Yossi Ovadya, Narmen Azazmeh, Benjamin Assouline, Yehuda Schlesinger, Rachel Kalifa, Shaul Horwitz, Yonatan Khalatnik, Anna Hochner-Ger, Ashraf Imam, Jonathan Abraham Demma, Eitan Winter, Hadar Benyamini, Sharona Elgavish, Areej A. S. Khatib, Karen Meir, Karine Atlan, Eli Pikarsky, Oren Parnas, Yuval Dor, Gideon Zamir, Ittai Ben-Porath, Valery Krizhanovsky

Summary: Cellular senescence limits tumourigenesis by blocking cell proliferation, but senescent cells can also promote tumour growth through paracrine effects. Senescent cells in early pancreatic lesions express a proinflammatory signature, and targeting these cells with the senolytic drug ABT-737 can reduce PanIN development and progression to pancreatic ductal adenocarcinoma. These findings suggest that eliminating senescent cells may be an effective preventive therapy for precancerous lesions.
Article Genetics & Heredity

Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group

Melyssa Aronson, Chrystelle Colas, Andrew Shuen, Heather Hampel, William D. Foulkes, Hagit Baris Feldman, Yael Goldberg, Martine Muleris, Kami Wolfe Schneider, Rose B. McGee, Kory Jasperson, Arun Rangaswami, Laurence Brugieres, Uri Tabori

Summary: CMMRD is the most aggressive cancer predisposition syndrome associated with multiorgan cancers, often presenting in childhood. A multidisciplinary international working group established seven diagnostic criteria for the diagnosis of CMMRD, including definitive and likely diagnostic criteria. The criteria incorporate genetic testing, ancillary tests, and clinical manifestations to determine a diagnosis, with a focus on appropriate surveillance and treatment for improved survival.

JOURNAL OF MEDICAL GENETICS (2022)

Article Chemistry, Multidisciplinary

pH- and miRNA-Responsive DNA-Tetrahedra/Metal-Organic Framework Conjugates: Functional Sense-and-Treat Carriers

Pu Zhang, Yu Ouyang, Yang Sung Sohn, Rachel Nechushtai, Eli Pikarsky, Chunhai Fan, Itamar Willner

Summary: The study presents the synthesis of stimuli-responsive hybrid structures composed of drug-loaded UiO-66 metal-organic framework nanoparticles, NMOFs, locked by DNA tetrahedra gates. These hybrid systems combine high drug loading capacity of NMOFs and effective cell permeation properties of DNA tetrahedra, releasing drugs under different stimuli.

ACS NANO (2021)

Article Oncology

A novel founder MSH2 deletion in Ethiopian Jews is mainly associated with early-onset colorectal cancer

I Kedar, L. Walsh, G. Reznick Levi, S. Lieberman, A. Abu Shtaya, S. Naftaly Nathan, I Lagovsky, R. Tomashov-Matar, M. Goldenberg, L. Basel-Salmon, L. Katz, O. Aleme, T. Yablonski Peretz, A. Hubert, D. Rothstein, S. Castellvi-Bel, T. Walsh, M. C. King, C. C. Pritchard, Z. Levi, E. Half, I Laish, Y. Goldberg

Summary: The report identifies a novel founder deletion in Lynch syndrome in Ethiopian Jews that is associated with early-onset colorectal cancer and liposarcoma, highlighting the importance of awareness for improved patient diagnosis, surveillance, and genetic counseling. Among carriers, age at first tumor diagnosis varied, with older generations diagnosed later in life compared to younger generations.

FAMILIAL CANCER (2022)

Article Oncology

Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance

Carol Durno, Ayse Bahar Ercan, Vanessa Bianchi, Melissa Edwards, Melyssa Aronson, Melissa Galati, Eshetu G. Atenafu, Gadi Abebe-Campino, Abeer Al-Battashi, Musa Alharbi, Vahid Fallah Azad, Hagit N. Baris, Donald Basel, Raymond Bedgood, Anne Bendel, Shay Ben-Shachar, Deborah T. Blumenthal, Maude Blundell, Miriam Bornhorst, Annika Bronsema, Elizabeth Cairney, Sara Rhode, Shani Caspi, Aghiad Chamdin, Stefano Chiaravalli, Shlomi Constantini, Bruce Crooks, Anirban Das, Rina Dvir, Roula Farah, William D. Foulkes, Zehavit Frenkel, Bailey Gallinger, Sharon Gardner, David Gass, Mithra Ghalibafian, Catherine Gilpin, Yael Goldberg, Catherine Goudie, Syed Ahmer Hamid, Heather Hampel, Jordan R. Hansford, Craig Harlos, Nobuko Hijiya, Saunders Hsu, Junne Kamihara, Rejin Kebudi, Jeffrey Knipstein, Carl Koschmann, Christian Kratz, Valerie Larouche, Alvaro Lassaletta, Scott Lindhorst, Simon C. Ling, Michael P. Link, Rebecca Loret De Mola, Rebecca Luiten, Michal Lurye, Jamie L. Maciaszek, Vanan MagimairajanIssai, Ossama M. Maher, Maura Massimino, Rose B. McGee, Naureen Mushtaq, Gary Mason, Monica Newmark, Garth Nicholas, Kim E. Nichols, Theodore Nicolaides, Enrico Opocher, Michael Osborn, Benjamin Oshrine, Rachel Pearlman, Daniel Pettee, Jan Rapp, Mohsin Rashid, Alyssa Reddy, Lara Reichman, Marc Remke, Gabriel Robbins, Sumita Roy, Magnus Sabel, David Samuel, Isabelle Scheers, Kami Wolfe Schneider, Santanu Sen, Duncan Stearns, David Sumerauer, Carol Swallow, Leslie Taylor, Gregory Thomas, Helen Toledano, Patrick Tomboc, An Van Damme, Ira Winer, Michal Yalon, Lee Yi Yen, Michal Zapotocky, Shayna Zelcer, David S. Ziegler, Stefanie Zimmermann, Cynthia Hawkins, David Malkin, Eric Bouffet, Anita Villani, Uri Tabori

Summary: Surveillance and early cancer detection are associated with improved overall survival (OS) for individuals with CMMRD. In patients undergoing surveillance, GI and other solid tumors, as well as 75% of brain cancers, were detected asymptomatically. Adherence to the surveillance protocol resulted in significantly better survival outcomes, with a 4-year OS of 79% for patients undergoing full surveillance.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Genetics & Heredity

Mild Phenotype of Wolfram Syndrome Associated With a Common Pathogenic Variant Is Predicted by a Structural Model of Wolframin

Adi Wilf-Yarkoni, Oded Shor, Avi Fellner, Mark Andrew Hellmann, Elon Pras, Hagit Yonath, Shiri Shkedi-Rafid, Lina Basel-Salmon, Lili Bazak, Ruth Eliahou, Lior Greenbaum, Hadas Stiebel-Kalish, Felix Benninger, Yael Goldberg

Summary: This study describes a common WFS1 gene variant in Ashkenazi Jews that leads to a milder disease phenotype. It was found that the disease onset caused by this variant is later in age but with relatively mild symptoms, correlated with the impact on protein thermodynamics.

NEUROLOGY-GENETICS (2021)

Article Oncology

Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications

Ido Laish, Eitan Friedman, Gili Levi-Reznick, Inbal Kedar, Lior Katz, Zohar Levi, Naama Halpern, Shani Parnasa, Aasem Abu-Shatya, Elizabeth Half, Yael Goldberg

Summary: This study identified 11 carriers from four seemingly unrelated Ashkenazi Jewish families who had pathogenic variants in both BRCA1/2 and DNA MMR genes. 73% of the double carriers had cancer, with a range of tumor types and ages at diagnosis. The findings suggest that the phenotype of double carriers is not associated with early disease onset or a more severe phenotype, which may have implications for genetic testing and treatment strategies.

BREAST CANCER RESEARCH AND TREATMENT (2021)

Review Cell Biology

Putative homeostatic role of cancer driver mutations

Avanthika Venkatachalam, Eli Pikarsky, Yinon Ben-Neriah

Summary: Somatic mutations, traditionally linked to cancer, have been found to also occur in nontransformed cells early in life. Some of these mutations, typically associated with driving cancer, can spread widely among noncancerous tissue cells, particularly intensifying with age or exposure to external stressors. In certain states, these classic driver mutations in normal cells may play beneficial roles in maintaining homeostasis during stress and tissue repair in aging cells.

TRENDS IN CELL BIOLOGY (2022)

Review Oncology

Immunotherapies for hepatocellular carcinoma

Josep M. Llovet, Florian Castet, Mathias Heikenwalder, Mala K. Maini, Vincenzo Mazzaferro, David J. Pinato, Eli Pikarsky, Andrew X. Zhu, Richard S. Finn

Summary: Liver cancer, specifically hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death globally. Traditional treatments involve specific drugs, but the emergence of immune checkpoint inhibitors has revolutionized the management of HCC.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Review Oncology

Nonmalignant Features Associated with Inherited Colorectal Cancer Syndromes-Clues for Diagnosis

Diana Haimov, Sari Lieberman, Sergi Castellvi-Bel, Maartje Nielsen, Yael Goldberg

Summary: Familiarity with nonmalignant features and comorbidities of cancer predisposition syndromes is important for clinicians to diagnose and interpret molecular test results. Genetic predisposition to colorectal cancer should be suspected in young patients, patients with significant family histories, multiple polyps, mismatch repair-deficient tumors, and in association with malignant or nonmalignant comorbidities. This knowledge can raise awareness, enable diagnosis, and assist in the process of genetic testing.

CANCERS (2022)

Article Cell Biology

Vav1 Promotes B-Cell Lymphoma Development

Batel Shalom, Marganit Farago, Yaser Salaymeh, Shulamit Sebban, Eli Pikarsky, Shulamit Katzav

Summary: Vav1 is normally expressed in the hematopoietic system and its mutations and overexpression are associated with malignancies. This study shows that Vav1 expression in epithelial tissues can lead to the development of B-cell lymphomas. The cross-talk between epithelial cells secreting CSF-1 and lymphocytes expressing CSF-1R may contribute to the generation of these lymphomas.
Article Oncology

Clinical Characteristics, Response to Platinum-Based Chemotherapy and Poly (Adenosine Phosphate-Ribose) Polymerase Inhibitors in Advanced Lung Cancer Patients Harboring BRCA Mutations

Johnathan Arnon, Michael Tabi, Yakir Rottenberg, Aviad Zick, Philip Blumenfeld, Tamar Hamburger, Eli Pikarsky, Eti Avraham, Leeby Levine, Aron Popovtzer, Tamar Yablonski-Peretz, Luna Kadouri, Hovav Nechushtan

Summary: BRCA mutations may play an oncogenic role in nonsmall cell lung cancer (NSCLC), and patients with NSCLC harboring these mutations are sensitive to poly (adenosine phosphate-ribose) polymerase inhibitors (PARPi) and platinum-based chemotherapy. Further prospective trials are needed for the treatment of NSCLC with BRCA mutations.

CANCERS (2023)

Review Cardiac & Cardiovascular Systems

Transcatheter tricuspid valve repair and replacement: a landscape review of current techniques and devices for the treatment of tricuspid valve regurgitation

Kusha Rahgozar, Edwin Ho, Ythan Goldberg, Mei Chau, Azeem Latib

Summary: This article provides a comprehensive overview of transcatheter tricuspid valve interventions, including anatomy, imaging characteristics, and treatment guidelines. It summarizes the current techniques for valve repair and replacement, highlighting devices and valves under investigation.

EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2021)

Article Oncology

Age at diagnosis of cancer in 185delAG BRCA1 mutation carriers of diverse ethnicities: tentative evidence for modifier factors

Yael Laitman, Rachel Michaelson-Cohen, Rakefet Chen-Shtoyerman, Yael Goldberg, Orit Reish, Rinat Bernstein-Molho, Ephrat Levy-Lahad, Noa Ephrat Ben Baruch, Inbal Kedar, D. Gareth Evans, Sara Haim, Shani Paluch-Shimon, Eitan Friedman

Summary: Germline pathogenic sequence variants in BRCA1 significantly increase the risk of developing breast and ovarian cancer. Differences in age at diagnosis of these cancers between Ashkenazi Jews and Iraqi Jews carrying identical BRCA1 PSVs suggest the presence of ethnic-specific modifier factors.

FAMILIAL CANCER (2021)

暂无数据